Ekso Bionics Holdings, Inc. (EKSO) — SEC Filings
Ekso Bionics Holdings, Inc. (EKSO) — 30 SEC filings. Latest: 8-K/A (May 5, 2026). Includes 14 8-K, 7 10-Q, 2 8-K/A.
View Ekso Bionics Holdings, Inc. on SEC EDGAR
Overview
Ekso Bionics Holdings, Inc. (EKSO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 7, 2025: Ekso Bionics Holdings, Inc. announced on November 5, 2025, a change in its board of directors. Specifically, the company elected two new directors, Dr. David Chen and Mr. David L. R. Smith, to its Board of Directors, effective immediately. This filing also disclosed compensatory arrangements for cer
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 3 bearish, 27 neutral. The dominant filing sentiment for Ekso Bionics Holdings, Inc. is neutral.
Filing Type Overview
Ekso Bionics Holdings, Inc. (EKSO) has filed 2 8-K/A, 7 10-Q, 14 8-K, 2 DEF 14A, 2 10-K, 1 SC 13G, 1 S-1/A, 1 DEFA14A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of EKSO's 23 recent filings, 3 were flagged as high-risk, 10 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $9.659M |
| Net Income | -$7.021M |
| EPS | N/A |
| Debt-to-Equity | 1.24 |
| Cash Position | $2.722M |
| Operating Margin | -91.3% |
| Total Assets | $21.661M |
| Total Debt | $11.982M |
Key Executives
- Dr. David Chen
- Mr. David L. R. Smith
- Scott G. Davis
Industry Context
Ekso Bionics operates in the highly competitive and rapidly evolving exoskeleton and robotic rehabilitation technology market. Key trends include increasing adoption in physical therapy, neurological rehabilitation, and industrial applications. However, the industry faces challenges related to high product costs, reimbursement policies, and the need for extensive clinical validation and regulatory approvals.
Top Tags
10-Q (5) · 8-K (4) · governance (3) · filing-update (3) · financials (3) · equity-sale (2) · filing (2) · Medical Devices (2) · Biotechnology (2) · material-agreement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash on hand | $2.722M | Decreased from $4.493M at Dec 31, 2024, highlighting liquidity concerns. |
| Accumulated Deficit | $257.722M | Indicates significant historical losses and ongoing financial strain. |
| Cash used in operating activities | $7.470M | For the nine months ended Sept 30, 2025, demonstrating negative operational cash flow. |
| Net loss (Q3 2025) | $1.421M | Improved from $2.072M in Q3 2024, but still a loss. |
| Net loss (9 months 2025) | $7.021M | Worsened from $7.917M in the same period of 2024, indicating increasing losses. |
| Revenue (Q3 2025) | $4.227M | Slight increase from $4.129M in Q3 2024, showing minimal growth. |
| Revenue (9 months 2025) | $9.659M | Significant decrease from $12.835M in the same period of 2024, indicating a revenue decline. |
| Cash runway estimate | Q1 2026 | Management estimates cash will fund operations only into this quarter, signaling urgent need for capital. |
| Banc of California loan paid off | $2.000M | Eliminated liquidity covenants but used restricted cash, impacting overall cash position. |
| Common shares outstanding | 2,623,233 | As of October 27, 2025, reflecting potential dilution from equity financings. |
| Net Loss Per Common Share | $0.001 | Consistent for both Q2 2025 and Q2 2024, indicating persistent unprofitability. |
| Total Comprehensive Loss | $141,429 | For the six months ended June 30, 2025, a significant increase from $10,000 in the prior year, highlighting worsening financial performance. |
| Retained Earnings Deficit | $1,480 | At June 30, 2025, an improvement from $2,605 at December 31, 2024, but still a deficit. |
| Common Shares Outstanding | 10,000 | As of June 30, 2025, representing the total shares available to common stockholders. |
| Total Assets | 141,429 | As of March 31, 2025 |
Frequently Asked Questions
What are the latest SEC filings for Ekso Bionics Holdings, Inc. (EKSO)?
Ekso Bionics Holdings, Inc. has 30 recent SEC filings from Jan 2024 to May 2026, including 14 8-K, 7 10-Q, 2 8-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of EKSO filings?
Across 30 filings, the sentiment breakdown is: 3 bearish, 27 neutral. The dominant sentiment is neutral.
Where can I find Ekso Bionics Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ekso Bionics Holdings, Inc. (EKSO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ekso Bionics Holdings, Inc.?
Key financial highlights from Ekso Bionics Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for EKSO?
The investment thesis for EKSO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ekso Bionics Holdings, Inc.?
Key executives identified across Ekso Bionics Holdings, Inc.'s filings include Dr. David Chen, Mr. David L. R. Smith, Scott G. Davis.
What are the main risk factors for Ekso Bionics Holdings, Inc. stock?
Of EKSO's 23 assessed filings, 3 were flagged high-risk, 10 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Ekso Bionics Holdings, Inc.?
Forward guidance and predictions for Ekso Bionics Holdings, Inc. are extracted from SEC filings as they are enriched.